Ayala Pharmaceuticals is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare cancers. The company’s lead candidates under development are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). The Company’s AL101 and AL102 assets were acquired by Immonume, Inc. in 2024.
